Circulating DNA/RNA Patent Landscape Report 2024

The nucleic acid-based therapeutics market was valued at USD 5.32 billion in 2023. It is expected to grow at a CAGR of 13.29% during the forecast period of 2024-2032 and attain a market value of USD 11.37 billion by 2032.

The market is expected to grow due to increasing advancements in nucleic acid sequencing and delivery technologies. This technology has huge potential for the development of personalized medicines. The rising demand for these technologies has led to a surge in the number of patent filings in recent years.

Patent Landscape Report Coverage

The circulating DNA/RNA patent landscape report provides a comprehensive and in-depth analysis of the patents in this growing industry. The key sections captured in the report for circulating DNA/RNA includes a thorough examination of the patent portfolios of key players, covering aspects such as the number of patents and types of technologies patented. It includes the latest trends, geographical distribution of patents, top IP player profiles, technological segmentation, and patent valuation. The breakdown of patents by technical segments is provided, giving more clarity on the specific areas of innovation within circulating DNA/RNA technologies.

The sequencing of tumor DNA has led to the development of new biomarkers, leading to possibilities for precision oncology. Detection of amplifications, somatic gene mutations, and gene fusions allows the delivery of targeted therapies in several cancer-types including breast cancer, lung cancer, colorectal, and melanoma. Hence, the patent claim language is crucial for the protection of these advanced technologies, and thus patent filings are on the rise.

Circulating DNA/RNA Patent Outlook

• There has been an increase in patent filings related to circulating DNA/RNA in the past few years. This surge in patent filing is impacted by expanding diagnostic and therapeutic applications, and advancements in technology. Moreover, this technology has a huge potential for the development of personalized medicine.

• Innovations in isolation methods, technologies for detection, and bioinformatics tools for data analysis has impacted the patent landscape significantly. Companies are actively protecting their innovations to secure competitive advantages.

• The United States and European countries are the most active applicants of circulating DNA/RNA technologies. This can be attributed to the presence of advanced technologies, and strong research and development activities.

What is Circulating DNA/RNA?

Circulating DNA and RNA refers to freely circulating DNA and RNA molecule fragments in the blood or other bodily fluids, such as serum, plasma, saliva, or urine. These fragments originate from cells undergoing normal turnover or cell death.

Circulating DNA/RNA can be detected and analyzed using multiple molecular biology techniques, including PCR, digital PCR, and next generation sequencing (NGS). This technique allows for the identification of specific mutations in DNA/RNA sequences. It also provides insights into disease progression, monitoring and assessment of treatment response.

The expanding applications of cDNA/RNA in cancer detection, non-invasive prenatal testing, monitoring treatment response, and studying disease progression has impacted the patent landscape significantly.

Circulating DNA/RNA Industry Growth Drivers

Advancements in Detection Technologies such as qPCR and NGS is Expected to Boost the Patent Industry Growth

Innovations in detection technologies such as quantitative PCR, digital PCR, and next-generation sequencing (NGS) have significantly improved the detection efficiency and sensitivity of circulating DNA and RNA. For instance, NGS-based detection has the potential to simultaneously sequence thousands of targets. Patents covering these technologies are crucial for companies, seeking to establish competitive advantages in the market.

Expanding Applications is Expected to Propel Circulating DNA/RNA Patent Industry Growth

The expanding applications for circulating DNA/RNA across a wide range of diseases, including oncology, infectious diseases, prenatal testing, and autoimmune diseases are likely to boost the number of patent applications in coming years.

For instance, in oncology, the presence of the circulating tumor cfDNA and its analysis allows the detection of cancer disease, as well as the monitoring and assessment of treatment response. In prenatal testing, the analysis of fetal cfDNA in maternal blood allows non-invasive prenatal testing, which can investigate chromosomal abnormalities. This method is an alternative to more invasive methods. The patents covering these diverse applications contribute to the growth of the patent landscape.

Circulating DNA/RNA Patent Segmentation

The report will cover the following sections in detail

Breakup by Technology

• Extraction & Preparation of Circulating DNA/RNA

• Detection & Analysis of these cfDNA/RNA

Breakup by Indication

• Oncology

• Infectious Diseases

• Prenatal Diagnostics

• Nervous System

• Transplantation

• Cardiovascular

Circulating DNA/RNA Patent Segmentation Analysis

The breakup based on technology includes extraction and preparation of circulating DNA/RNA as well as the detection and analysis of these cfDNA/RNA. Circulating DNA/RNA investigations have been conducted with the chosen patent families labelled based on the platforms to which they pertain.

For instance, QIAGEN offers QIAamp circulating nucleic acid kits. It simplifies the isolation and purification of cfDNA and RNA from serum or plasma. The detailed technological data will be provided for all specified segments classified in this report.

Circulating DNA/RNA Patent Jurisdiction Analysis

The United States is one of the leading jurisdictions for circulating DNA/RNA patents, having around 129,000+ patents. The presence of major companies, well-established healthcare infrastructure, advanced research and development activities and strong legal framework contributes to the regional patent landscape significantly.

Patent Profile of Key Companies

Among the players with circulating DNA/RNA patent families, new entrants have been identified, which can be either established companies or startups developing their first technology in the field. Some of the major companies mentioned in this report (a non-exhaustive list) are as follows:

Illumina Inc.

Illumina, Inc., founded in 1998, and headquartered in the United States, engages in the development, manufacturing, and marketing of integrated systems for the analysis of genetic variation and biological function. The company has filed various patents in the field of circulating DNA/RNA.

Novartis AG

Novartis AG, founded in 1996, and headquartered in Switzerland is a global pharmaceutical company, involved in the development of therapies in multiple areas including oncology, respiratory diseases, neurological disorders, and diabetes among others. The company is developing innovative RNA-targeting therapies which have the potential to target and reduce tumours.

Other companies include Nantomics (NantWorks, LLC), Genentech Inc., and Spot Biosystems Ltd, among others.

Reasons to Purchase this Report

The circulating DNA/RNA patent report provides information on the intellectual property (IP) position and strategy of key players. This report can help companies and players looking to enter or invest in this field by -

• Competitive Advantage: The landscape reveals the market leaders, potential partners and innovators also makes it understandable which companies have important patents in this field of circulating DNA/RNA.

• Innovation Insights: The patent analysis reveals new innovations and technologies in circulating DNA/RNA.

• Market Positioning: Companies with strong patent portfolios gain a competitive advantage because their intellectual property assets differentiate their products. Understanding their intellectual property strategy reveals the market position of new entrants and potential barriers to entry.

• Risk Assessment: In technology-intensive fields such as mRNA cancer therapeutics, risks of IP infringement are common. Analyzing patent landscapes helps companies assess risk, develop mitigation strategies, and inform licensing, partnering, and acquisition decisions.

Key Questions Answered in the Circulating DNA/RNA Patent Landscape Report

• Who are the key players in the circulating DNA/RNA patent landscape?
• How is the patent portfolio distributed geographically?
• What are the emerging trends in circulating DNA/RNA patents?
• How has the patent landscape evolved over time?
• What are the strategic insights for market players and investors?
• What is the technological focus of patents in the circulating DNA/RNA industry?
• How do patent strategies impact competitive advantage?
• What are the implications of patent filings in circulating DNA/RNA?
• What are the challenges and opportunities in the circulating DNA/RNA patent landscape?
• What are the regulatory and legal considerations?
• What technological innovations have recently emerged in circulating DNA/RNA?

Related Reports

Global Nucleic Acid Amplification Testing Market

Global DNA Sequencing Products Market

Global Cancer Immunotherapy Market

Global Antisense and RNAi Therapeutics Market